Menu
Search
|

Menu

Close
X

Sorrento Therapeutics Inc SRNE.OQ (NASDAQ Stock Exchange Capital Market)

8.75 USD
-- (--)
As of Feb 16
chart
Previous Close 8.75
Open --
Volume --
3m Avg Volume 417,546
Today’s High --
Today’s Low --
52 Week High 9.50
52 Week Low 1.50
Shares Outstanding (mil) 76.54
Market Capitalization (mil) 137.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
131
FY16
8
FY15
5
EPS (USD)
FY17
-0.213
FY16
-1.308
FY15
-1.237
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.72
5.77
Price to Book (MRQ)
vs sector
1.49
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
28.72
16.52
LT Debt to Equity (MRQ)
vs sector
28.72
12.22
Return on Investment (TTM)
vs sector
-12.13
14.43
Return on Equity (TTM)
vs sector
-29.69
16.13

EXECUTIVE LEADERSHIP

William Marth
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Henry Ji
President, Chief Executive Officer, Director, Since 2012
Salary: $425,000.00
Bonus: $157,500.00
Kevin Herde
Chief Financial Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Mike Royal
Executive Vice President - Clinical and Regulatory Affairs, Since 2014
Salary: $287,500.00
Bonus: $50,000.00
Miranda Toledano
Executive Vice President - Corporate Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4955 Directors Pl
SAN DIEGO   CA   92121-3836

Phone: +1858.2034100

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

SPONSORED STORIES